603077 Sichuan Hebang Biotechnology
- 1.81
- -0.06-3.21%
Sichuan Hebang Biotechnology News
Sichuan Hebang Biotechnology (603077.SH): spent a cumulative amount of 44.635 million yuan to repurchase 0.25% of the shares.
On June 5th, Gelunhui reported that Sichuan Hebang Biotechnology (603077.SH) has cumulatively repurchased 21,860,700 shares through the Shanghai Stock Exchange's centralized bidding trading system as of May 31, 2024, accounting for 0.25% of the company's total share capital. The highest purchase price was 2.14 yuan/share and the lowest was 1.97 yuan/share, and the total amount paid was 44,635,156.36 yuan.
Sichuan Hebang Biotechnology (SHSE:603077) Shareholders Have Lost 21% Over 1 Year, Earnings Decline Likely the Culprit
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. Investors i
Hebang Biotech (603077.SH): Methionine project running at full capacity
Gelonghui, May 10, 丨 Hebang Biotech (603077.SH) said on the investor interactive platform that the company's methionine project is running at full capacity, and the company's methionine customers have covered well-known domestic agricultural and animal husbandry enterprises such as Muyuan Co., Ltd., New Hope, Haida Group, Shengnong Co., Ltd.; the company will create more profits for the company through continuous process optimization and sales strategy adjustments.
Hebang Biotech (603077.SH): Has repurchased a total of 114.902 million shares
Gelonghui, May 7, 丨 Hebang Biotech (603077.SH) announced that as of April 30, 2024, the company had repurchased a total of 11,490,200 shares through the Shanghai Stock Exchange system, accounting for 0.13% of the company's total share capital. The highest purchase price was 2.13 yuan/share, the lowest price was 1.98 yuan/share, and the total amount paid was 23,484,329.85 yuan.
Express News | Hebang Biotech: Plans to repurchase shares for 100 million yuan to 200 million yuan
Changes in A-shares | Hebang Biotech's net profit fell 92% year-on-year in the first quarter
Gelonghui April 22 | Hebang Biotech (603077.SH) fell to a halt, reaching a new low of 2.13 yuan since August 2021, with a market value of 18.9 billion yuan. According to news, the company achieved operating income of 1,999 billion yuan in the first quarter, a year-on-year decrease of 16.51%, and realized net profit of 29.79 million yuan, a year-on-year decrease of 92.49%. Net cash flow from operating activities was 433 million yuan, which turned negative year-on-year. The balance ratio was 23.26%, up 7.17 percentage points from the previous year.
Hebang Biotech (603077.SH) announced its 2023 annual results, with net profit of 1,283 billion yuan, a year-on-year decrease of 66.29%
Hebang Biotech (603077.SH) disclosed its 2023 annual report, and the company achieved 88 revenue in 2023...
Hebang Biotech (603077.SH): A total cost of 286 million yuan to buy back 1.41% of the shares
Gelonghui, April 1, 丨 Hebang Biotech (603077.SH) announced that as of March 31, 2024, the company had repurchased a total of 124,418,767 shares through the Shanghai Stock Exchange system, accounting for 1.41% of the company's total share capital. The highest purchase price was 2.46 yuan/share, the lowest price was 2.27 yuan/share, and the total amount paid was 285,880,508.11 yuan.
Sichuan Hebang Biotechnology (SHSE:603077) Has Some Way To Go To Become A Multi-Bagger
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employe
Hebang Biotech (603077.SH): The company's photovoltaic glass production line is running at full capacity
Gelonghui, March 22丨Hebang Biotech (603077.SH) said on the investor interactive platform that the company's photovoltaic glass production line is running at full capacity. For related product sales data, please pay attention to the company's annual report to be disclosed on April 27, 2024.
Hebang Biotech (603077.SH): Not considering selling photovoltaic projects
On March 15, Gelonghui Biotech (603077.SH) said on the investor interactive platform that the company is not considering selling photovoltaic projects.
Huaan Securities: Supply improvements combined with stock replenishment cycles, methionine price center is expected to move upward
The pattern of methionine supply and demand has gradually been rebalanced, and the competitiveness of domestic enterprises has been steadily improving.
Hebang Biotech (603077.SH) has spent 285 million yuan to buy back 1.41% of its shares
Hebang Biotech (603077.SH) issued an announcement. As of February 29, 2024, the company approved Shanghai Securities...
Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) Looks Inexpensive But Perhaps Not Attractive Enough
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 30x, you may consider Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) as an attractive investm
Hebang Biology (603077.SH): It has Mabian Yanfeng phosphate ore and Hanyuan Liujiashan phosphate deposit. The total resource reserves of the two phosphate mines are 9.91 million tons
Gelonghui, Feb. 23 | Hebang Biotech (603077.SH) said on the investor interactive platform that the company owns the Mabian Yanfeng phosphate mine and the Hanyuan Liujiashan phosphate deposit, with total reserves of 90.91 million tons; at the same time, AEV, an Australian listed company with a subsidiary of the company, has rich reserves of high-grade phosphate resources and mining licenses in the Northern Territory of Australia.
Hebang Biotech (603077.SH): Shares expropriated by majority shareholders cannot participate in securities lending business
On February 8, Gelonghui Biotech (603077.SH) said on the investor interactive platform that after special confirmation from us and the pledgeholder, shares expropriated by the majority shareholders cannot participate in the securities lending business.
Hebang Biotech (603077.SH): It has spent 281 million yuan to repurchase 1.38% of the shares
On February 7, Ge Longhui (603077.SH) announced that as of February 7, 2024, the company had repurchased 122 million shares through centralized bidding transactions through the Shanghai Stock Exchange system, accounting for 1.38% of the company's total share capital, an increase of 0.54% compared with the previous disclosure. The highest purchase price was 2.46 yuan/share, the lowest price was 2.27 yuan/share, and the total amount paid was 281 million yuan.
Hebang Biotech (603077.SH): A total cost of 170 million yuan to buy back 0.84% of shares
Gelonghui, February 4, 丨 Hebang Biotech (603077.SH) announced that as of February 4, 2024, the company had repurchased a total of 74,025,687 shares through the Shanghai Stock Exchange system, accounting for 0.84% of the company's total share capital. The highest purchase price was 2.38 yuan/share, the lowest price was 2.28 yuan/share, and the total amount paid was 169,997,489.57 yuan.
Sichuan Hebang Biotechnology (SHSE:603077) Pulls Back 3.4% This Week, but Still Delivers Shareholders Notable 22% CAGR Over 3 Years
One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. For example, Sichuan Hebang Biotechnology Co
Hebang Biotech (603077.SH): A total cost of 684.759 million yuan to buy back 0.33% of shares
Gelonghui, January 31, 丨 Hebang Biotech (603077.SH) announced that as of January 31, 2024, the company had repurchased 29,558,535 shares through the Shanghai Stock Exchange system, accounting for 0.33% of the company's total share capital. The highest purchase price was 2.38 yuan/share, the lowest price was 2.28 yuan/share, and the total amount paid was 68,475,863.50 yuan.
Analysis
Price Target
No Data
